Since 1993, intensive insulin therapy has remained the mainstay of treatment of type 1 diabetes, albeit with a substantial self-care burden placed upon the person living with type 1 diabetes until the creation of advanced technologies that have eased many self-care demands. This evidence concerns the gene INS and type 1 diabetes mellitus.